AL
SRPT icon

Airain Ltd’s Sarepta Therapeutics SRPT Stock Holding History

Airain Ltd’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,776
Closed -$300K – 1043
2015
Q4 		$300K Buy
+7,776
New +$252K 0.02% 604
2013
Q3 		– Sell
-7,717
Closed -$294K – 645
2013
Q2 		$294K Buy
+7,717
New +$276K 0.04% 387

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Airain Ltd's SRPT Position: Q1 2016 in Review

Airain Ltd sold out of Sarepta Therapeutics (SRPT) in Q1 2016, closing a stake of 7,776 shares — an estimated $300K sold.

Airain Ltd first reported a position in SRPT in Q2 2013 and held it in 2 quarters. The position peaked at $300K in Q4 2015. 132 funds tracked by Wall St. Rank hold SRPT as of Q1 2016.

  • Airain Ltd reported no remaining Sarepta Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 7,776 Sarepta Therapeutics shares in Q1 2016, an estimated $300K.
  • Airain Ltd first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 2 quarters.
  • Airain Ltd's Sarepta Therapeutics position peaked at $300K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.